Honoring our roots, caring for our community.

FDA-approved for one specific indication

PT-141 (Bremelanotide)

A melanocortin receptor agonist. Bremelanotide (Vyleesi®) is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; other uses are investigational.

Evidence-based care Individualized plan
PT-141 (Bremelanotide)

Overview and regulatory status

A melanocortin receptor agonist. Bremelanotide (Vyleesi®) is FDA-approved for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women; other uses are investigational.

Availability, if any, is decided only after an individual evaluation by a licensed provider.

Safety first

Who should not use it

  • Severe high blood pressure
  • Certain heart conditions or fluid restriction
  • Pregnancy or breastfeeding (consult your provider)
  • All current medications and supplements are reviewed for interactions

Next step

Talk with a provider first

Every plan starts with a medical evaluation by a licensed provider.

Request a consultation

Information on this page is educational and does not replace medical evaluation. Treatment options are determined individually.